SixPeaks Bio' chair Alex Mayweg (L) and CEO Philip Just Larsen

Ver­sant has a new obe­si­ty biotech. As­traZeneca has the op­tion to buy it

As­traZeneca is step­ping fur­ther in­to the obe­si­ty field with an op­tion for a fledg­ling start­up that seeks to pre­serve mus­cle mass, a com­mon con­cern for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.